Rüdiger Smolnik

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial

Pascal Vranckx, Marco Valgimigli, Lars Eckardt et al. · The Lancet · 2019 · 659 citations

Medicine, Cardiology, Pharmacology +16

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Renate B. Schnabel, Elena Andreassi Marinelli, Elena Arbelo et al. · EP Europace · 2022 · 178 citations · Full text

Medicine, Cardiology, Clinical Cardiology +7

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial

Stefan H. Hohnloser, A. John Camm, Riccardo Cappato et al. · European Heart Journal · 2019 · 170 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin_4–10Decreases Body Fat in Humans¹

Horst L. Fehm, Rüdiger Smolnik, Werner Kern et al. · The Journal of Clinical Endocrinology & Metabolism · 2001 · 113 citations · Full text

Life Sciences, Endocrinology, Physiology +17

Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli et al. · American Heart Journal · 2017 · 86 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17